Key result
Device-based autonomic regulation therapy is reviewed as a potential therapeutic approach to restore autonomic balance in the management of heart failure with reduced ejection fraction.
Why the study?
Does device-based autonomic regulation therapy improve outcomes in patients with heart failure with reduced ejection fraction?
Does device-based autonomic regulation therapy improve outcomes in patients with heart failure with reduced ejection fraction?
This review summarizes current clinical trials investigating device-based autonomic regulation therapy for restoring autonomic balance in heart failure with reduced ejection fraction.
Heart failure (HF) is associated with significant morbidity and mortality and an increasing economic burden. The persistence of HF's risk factors, coupled with an aging population, also leads to an increase in its incidence and prevalence. It is well established that sympathetic hyperactivity and parasympathetic withdrawal are instrumental in the development and worsening of HF. Therefore, restoring autonomic balance to the cardiovascular system is an attractive therapeutic approach. The following is a review of current clinical trials of device-based autonomic regulation therapy in the management of HF with a reduced ejection fraction.
No takes yet. Share an insight, caveat, or question.
Wagner et al. (2017) conducted a review in Heart failure with reduced ejection fraction. Device-based autonomic regulation therapy was evaluated. Device-based autonomic regulation therapy is reviewed as a potential therapeutic approach to restore autonomic balance in the management of heart failure with reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: